# A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

> **NCT06677307** · PHASE1,PHASE2 · TERMINATED · sponsor: **Korro Bio, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Alpha-1 Anti-trypsin Deficiency
- AATD

## Interventions

- **DRUG:** KRRO-110

## Key facts

- **NCT ID:** NCT06677307
- **Lead sponsor:** Korro Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-01-13
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-15
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** The study was terminated for business decision reasons.
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06677307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06677307, "A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06677307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*